1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
CKD Bio Corp.

CKD Bio Corp.

KKRX:063160
12,500.00
KRW
-250.00
(-1.96%)
-1,958.09EPS
72.14BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18,628.61
19,713.65
19,808.47
20,979.65
21,946.53
23,116.49
26,743.63
23,023.52
25,931.91
28,443.94
29,230.35
31,307.94
29,150.66
28,820.61
Basic EPS, GAAP
307.62
-204.76
1,235.24
1,751.43
1,488.57
1,477.14
2,391
1,147
-1,199
-3,044.61
-4,410
1,586
-526
-1,958.09
Free Cash Flow per Basic Share
1,264.32
1,547.5
449.22
880.6
2,000.56
-274.15
-6,042.72
-10,677.52
-4,847.31
-1,902.09
-3,281.59
1,776.99
-1,996.49
-1,794.18
Dividend per Share
333.21
95.05
95.24
333.28
381
380.93
199.99
189.56
200.03
100
- -
- -
99.91
- -
Book Value per Share
22,999.49
22,622.8
23,649.69
25,095.77
26,373.47
27,416.15
30,892.63
30,759.97
29,437.2
26,941.4
22,425.33
23,880.81
23,156.5
21,795.54
Tangible Book Value per Share
22,984.08
22,612.34
23,640.55
25,087.84
26,146.23
27,059.61
30,461.59
30,227.52
28,931.74
26,241.61
21,306.55
22,704.24
22,138.46
20,884.13
Basic Weighted Avg Shares
5
5
5
5
5
5
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
100,371
106,390
106,691
113,013
118,187
124,510
137,184
124,600
142,238
156,042
160,353
171,756
160,071
158,119
Operating Margin (%)
1.94
-2.48
7.54
10.28
7.64
5.63
11.23
6.11
-8.04
-9.49
-12.57
6.38
2.25
-5.1
Depreciation Expense
11,713
11,416
10,904
8,997
9,068
8,956
9,777
12,235
16,984
17,938
17,578
16,686
15,655
15,899
Net Income, GAAP
1,657
-1,105
6,653
9,435
8,016
7,956
12,265
6,207
-6,577
-16,703
-24,193
8,701
-2,888
-10,743
Effective Tax Rate (%)
12.91
- -
17.9
22.11
16.85
14.4
21.57
12.07
- -
- -
- -
5.59
- -
- -
Profit Margin (%)
1.65
-1.04
6.24
8.35
6.78
6.39
8.94
4.98
-4.62
-10.7
-15.09
5.07
-1.8
-6.79
Working Capital
43,166
44,290
48,422
53,714
57,394
54,628
35,018
42,268
60,031
41,874
13,151
24,531
-15,804
7,419
LT Debt
3,453
282
226
169
113
2,056
20,239
59,882
89,348
81,910
70,423
60,327
18,300
45,138
Total Equity
123,874
121,845
127,376
135,164
142,046
147,662
158,463
168,748
161,491
147,799
123,024
131,009
127,036
119,569
Return on Invested Capital (%)
1.18
- -
5.03
6.48
5.17
4.07
7.19
3.07
- -
- -
- -
3.89
- -
- -
Return on Capital (%)
1.56
- -
5.07
6.77
5.54
5.37
7.3
3.1
- -
- -
- -
5.14
- -
- -
Return on Common Equity (%)
1.34
-0.9
5.34
7.19
5.78
5.49
8.01
3.79
-3.98
-10.8
-17.87
6.85
-2.24
-8.58

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
126,660
100,909
102,800
LT Borrowings
17,250
45,850
44,350
LT Finance Leases
1,050
925
788
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
111,639
102,862
72,140

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
136,237
136,375
132,482
Cash, Cash Equivalents & STI
1,497
1,026
588
Accounts Receivable, Net
34,708
36,712
37,797
Inventories
96,766
95,556
91,463
Total Current Liabilities
152,042
123,669
125,063
Payables & Accruals
- -
- -
- -
ST Debt
126,660
100,909
102,800
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.29%
-5.22%
-3.03%
Free Cash Flow
178.62%
-81.77%
-212.46%
Net Income, GAAP
-24.55%
-55.26%
-133.2%
Sales/Revenue/Turnover
4.38%
5.39%
-6.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
45,536
50,914
43,885
31,421
171,756
2025
42,521
41,211
34,120
42,219
160,071
2026
40,695
41,086
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
516
803
52
215.04
1,586
2025
164
-87
-397.25
-205.84
-526
2026
-369.87
-985
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
99.91
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wan-Gap Park
Full Time Employees
533
Sector
Health technology
Industry
Pharmaceuticals: major
Address
8 Chungjeong-ro Seoul SL South Korea 03742
IPO Date
Dec 11, 2001
Website
ckdbio.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
CKD Bio Corp. (063160.KS) develops, manufactures, and markets biopharmaceuticals and medical devices with a focus on dialysis-related products, cell therapy solutions, and regenerative medicine technologies. The company offers hemodialysis machines and related consumables including dialyzers, blood tubing sets, and bicarbonate cartridges under its proprietary brands; peritoneal dialysis solutions and systems; and advanced offerings such as cell separation devices, bio-reactors for stem cell culture, and platelet-rich plasma preparation systems. CKD Bio operates primarily in South Korea, with distribution networks extending to Asia, Europe, and select international markets, and maintains its headquarters in Chungcheongbuk-do, South Korea, where it was founded in 2007 as a subsidiary of CKD Corporation. In the biopharma segment, the company provides contract development and manufacturing organization (CDMO) services for biologics and biosimilars, alongside research and development in antibody-drug conjugates and gene therapies targeting oncology and immunology indications. Its medical device portfolio emphasizes renal care solutions like portable dialysis monitors and automated peritoneal dialysis cyclers, complemented by wound healing products utilizing growth factor technologies. CKD Bio serves healthcare providers, hospitals, dialysis clinics, and research institutions as primary customers, leveraging vertical integration from R&D to commercialization. Recent strategic developments include the expansion of its cell therapy platform with the launch of a new GMP-compliant manufacturing facility in 2024 to scale production of allogeneic stem cell products; a partnership agreement with a leading Japanese biotech firm in early 2025 for co-development of CAR-T therapies targeting solid tumors; and a Series B funding round of KRW 50 billion in mid-2025 to support entry into the U.S. market via FDA submissions for its next-generation dialyzer series. The company also completed the acquisition of a minority stake in a European regenerative medicine startup in late 2024, enhancing its exosome-based therapeutics pipeline. These initiatives reflect CKD Bio's shift toward diversified revenue streams beyond traditional dialysis, with increased emphasis on global clinical trials and digital health integrations for remote patient monitoring.